As SER-252 advances into its second dose cohort, Serina is building a case that improving how a medicine reaches patients can be as consequential as discovering the medicine itself.
Serina Therapeutics, Inc. (NYSE American: SER) is pursuing an appealing proposition in biotechnology:…